A Phase 1 Placebo-Controlled Dose Escalating Study to Evaluate the Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of ARO-ATXN2 in Adult Subjects With Spinocerebellar Ataxia Type 2 (NCT06672445)
AROATXN2
This trial is No longer recruiting
Registration number NCT06672445
Program & service
This trial is being run with the Brain service, and as part of the Neurology program.
Trial phase
Phase 1
Trial participation type
This trial has been designed for the Clinical Research of a Drug.
Principal investigator
Dr Kelly Bertram
More information
To find out more about this clinical trial, please review full details on the ANZCTR website.
View on ANZCTR